TNFSF11 and osteoporosis: Because of severe osteoporosis induced by steroids, in July 2018 she started treatment with denosumab, a human monoclonal antibody targeting the key bone resorption mediator RANKL, which is administered subcutaneously once every 6 months and prevents bone remodeling (3).